EcoDrugPlus

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSSDUG00000010182
Gene Symbol: PIK3CB
3 Cross references
216 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSSDUG00000007681
Gene Symbol: PIK3CD
3 Cross references
211 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSSDUG00000015284
Gene Symbol: PIK3CG
3 Cross references
213 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSSDUG00000005337
Gene Symbol: PDE10A
3 Cross references
205 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSSDUG00000002551
Gene Symbol: PDE3A
3 Cross references
215 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSSDUG00000023138
Gene Symbol: PDE3B
3 Cross references
217 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSSDUG00000020801
Gene Symbol: PDE4A
3 Cross references
201 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSSDUG00000012442
Gene Symbol: PDE4B
3 Cross references
227 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSSDUG00000000227
Gene Symbol: PDE4D
3 Cross references
235 Possible Orthologues:

Phosphodiesterase 5a

Ensembl ID : ENSSDUG00000003319
Gene Symbol: PDE5A
3 Cross references
221 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSSDUG00000014337
Gene Symbol: PDE7A
3 Cross references
227 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSSDUG00000012904
Gene Symbol: PDE7B
4 Cross references
189 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).